Join to View Full Profile
955 Main StBuffalo, NY 14203
Phone+1 716-829-2802
Dr. Yao is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Jacobs School of Medicine and Biomedical Sciences at the University at BuffaloClass of 2023
Publications & Presentations
PubMed
- Diet quality and cardiometabolic health in breast cancer survivors: the Pathways Study.Isaac J Ergas, Richard K Cheng, Janise M Roh, Jacob K Kresovich, Carlos Iribarren
Breast Cancer Research and Treatment. 2025-05-01 - 2 citationsUnder-Representation and Under-Reporting of Minoritized Racial and Ethnic Groups in Clinical Trials on Immune Checkpoint Inhibitors.Alfredo V Chua Jr, Jennifer Delmerico, Haiyang Sheng, Xin-Wei Huang, Emily Liang
JCO Oncology Practice. 2025-03-01 - An Intermittent Fasting Intervention for Black Adults Can Be Feasibly Implemented in Black Churches: A Cluster Randomized Controlled Pilot Study.Karen H Kim Yeary, Detric Johnson, Narseary Harris, Han Yu, Frances G Saad-Harfouche
Journal of the Academy of Nutrition and Dietetics. 2025-02-01
Press Mentions
Why Are Breast Cancer Rates Rising Among Asian-American and Pacific Islander Women?February 7th, 2025- Wilmot, Roswell Get Additional Grants Totaling $13.5 MillionDecember 15th, 2023
- Polygenic Risk Score Shows Potential to Predict Survival Outcomes in Breast Cancer PatientsJune 3rd, 2024
Grant Support
- A Multi-Institute Survivorship Study of Patients Living with Advanced Cancer Who Have Had Durable Response to Immune Checkpoint InhibitorsROSWELL PARK CANCER INSTITUTE CORP2023–2028
- A Multi-Institute Survivorship Study of Patients Living with Advanced Cancer Who Have Had Durable Response to Immune Checkpoint InhibitorsROSWELL PARK CANCER INSTITUTE CORP2023–2028
- A Multi-Institute Survivorship Study of Patients Living with Advanced Cancer Who Have Had Durable Response to Immune Checkpoint InhibitorsROSWELL PARK CANCER INSTITUTE CORP2023–2028
- A Multi-Institute Survivorship Study of Patients Living with Advanced Cancer Who Have Had Durable Response to Immune Checkpoint InhibitorsROSWELL PARK CANCER INSTITUTE CORP2023–2028
- A Multi-Institute Survivorship Study of Patients Living with Advanced Cancer Who Have Had Durable Response to Immune Checkpoint InhibitorsROSWELL PARK CANCER INSTITUTE CORP2023–2028
- Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 in a Community Oncology SettingROSWELL PARK CANCER INSTITUTE CORP2021–2027
- Tumor Immune Contexture and Breast Cancer Disparities: A Multi-Disciplinary Study in Women of African and European AncestryROSWELL PARK CANCER INSTITUTE CORP2020–2025
- Insights from Asian Populations into Disparities in Breast Cancer Prognosis and OutcomesUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2020–2025
- Somatic Mutations and Their Etiological Determinants for Breast Cancer in African American WomenROSWELL PARK CANCER INSTITUTE CORP2019–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
